Continuing advances in cell and gene therapy (CGT) are transforming how pharmaceutical companies treat, cure, and potentially eradicate a range of diseases. However, developing, manufacturing, and getting a CGT to patients is both complex and expensive. Not only do they face a range of evidence-generation challenges but up-to-date information on the market access policies and Health Technology Assessment (HTA) body processes can be limited for this burgeoning modality with unique particularities. With a considerable number of CGTs anticipated to be developed and approved over the coming years, it is essential manufacturers remain informed about the evolving market access, pricing and reimbursement landscape and routes to market.
Access CGT is a comprehensive repository which provides quarterly surveillance of the CGT market access and policy space, layered with expertise from our thought leaders and supplemented with tailored insights from our expert payer network which includes key regulatory and market access stakeholders.